# IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

MONTEREY RESEARCH, LLC : CIVIL ACTION

Plaintiff :

: NO. 19-2083

v. :

•

QUALCOMM INCORPORATED :

Defendants

## **ORDER**

**AND NOW**, this 15<sup>th</sup> day of March 2021, upon consideration of Defendants' *motion to* stay pending inter partes review, [ECF 70, 71], Plaintiff's opposition thereto, [ECF 72], and Defendant's reply, [ECF 75], it is hereby **ORDERED** that the motion is **GRANTED**, and this matter is **STAYED** pending the *inter partes* review of the patents-in-suit.<sup>1</sup>

Generally, a decision to stay litigation lies within the sound discretion of the court. See Cost Bros., Inc. v. Travelers Indem. Co., 760 F.2d 58, 60 (3d Cir. 1985); Ethicon, Inc. v. Quigg, 849 F.2d 1422, 1426–27 (Fed. Cir. 1988) (citations omitted) ("Courts have inherent power to manage their dockets and stay proceedings, including the authority to order a stay pending conclusion of a PTO reexamination."). Granting or denying a motion to stay is within the broad discretionary powers of the court. See Dentsply Int'l, Inc. v. Kerr Mfg. Co., 734 F. Supp. 656, 658 (D. Del.1990) (citing Bechtel Corp. v. Local 215, Laborers' Int'l Union of N. Am., 544 F.2d 1207, 1215 (3d Cir. 1976)). In deciding a motion to stay, the court considers three factors: "(1) whether the granting of a stay would cause the non-moving party to suffer undue prejudice from any delay or allow the moving party to gain a clear tactical advantage over the non-moving party; (2) whether a stay will simplify the issues for trial; and (3) whether discovery is complete and a trial date set." Cephalon, Inc. v. Impax Labs., Inc., 2012 WL 3867568, at \*2 (D. Del. Sept. 6, 2012). Here, on balance, the factors weigh in favor of a stay.

In the operative amended complaint, Plaintiff Monterey Research, LLC ("Plaintiff" or "Monterey"), a non-practicing entity focused on monetizing patents it obtained from other companies, asserts claims against Defendants Qualcomm Incorporated, Qualcomm Technologies, Inc., and Qualcomm CDMA Technologies Asia-Pacific Pte Ltd. ("Defendants" or "Qualcomm") for direct and indirect patent infringements premised on Plaintiff's ownership of eight (8) patents: the '625 patent, the '805 patent, the '573 patent, the '134 patent, the '516 patent, the '407 patent, the '727 patent, and the '797 patent (the "Asserted Patents"). Qualcomm has filed petitions for *inter partes* review ("IPR") with the United States Patent and Trademark Office, Patent Trial and Appeal Board ("PTAB") challenging claims of each of the Asserted Patents. In addition, co-defendant AMD has filed IPR petitions against all asserted claims of the '407 and '134 patents, as well as certain claims of the '805 patent. As of the date of this Order, the PTAB has granted Defendants' petitions with respect to three of the eight patents-in-suit, with five petitions challenging the remaining patents yet to be decided. Defendants seek a stay of this litigation pending the PTAB's decisions with respect to the challenged patents.

### **Undue Prejudice**

In determining whether there is undue prejudice, the court weighs a variety of factors, including: "the timing of the request for reexamination, the timing of the request for stay, the status of the reexamination proceedings, and the relationship of the parties." Boston Scientific Corp. v. Cordis Corp., 777 F. Supp. 2d 783, 789 (D. Del. 2011). The mere potential for delay does not in itself establish undue prejudice. See, e.g., BodyMedia, Inc. v. Basis Sci., Inc., 2013 WL 2462105, at \*1 (D. Del. Jun. 6, 2013). After considering these three factors, this Court concludes that there is no evidence of undue prejudice. Regarding the timing of the request for reexamination, Defendants filed their IPR petitions between August 20, 2020, and November 5, 2020, within a few months of Monterey having filed its operative amended complaint, and before the initial case management conference, substantial discovery disclosures, contention disclosures, or claim construction disclosures and proceedings. Defendants' filing was also well within the one-year timeframe that the statute provides. See 35 U.S.C. § 315(b). In addition, the timing of the request for stay suggests no dilatory motive, as Defendants filed the underlying motion to stay less than four months after filing its last IPR petition. The PTAB has granted the petitions as to three of the asserted patents (five petitions which challenge the other two patents remain outstanding). The relationship of the parties also favors granting a stay since Plaintiff is a non-practicing entity and does not compete with Defendants. See AIP Acquisition LLC v. Level 4 Commc'ns, LLC, 2014 WL 1264200, at \*3 (D. Del. Jan. 9, 2014) (holding that because plaintiff was "not a direct competitor" it would not suffer any undue prejudice); Uniloc 2017 LLC v. Vudu, Inc., Civ. A. No. 19-0183, DI 72 at \*2 (D. Del. Mar. 26, 2020 ("[B]ecause Plaintiff is a nonpracticing entity that does not compete with [defendant] and thus any alleged harm it may suffer is purely monetary, Uniloc will not be unduly prejudiced by a stay."). This factor, therefore, favors a stay.

## **Simplification of Issues**

A stay is likely to simplify the issues for trial. The PTAB has granted IPR with respect to three of the eight asserted patents-in-suit. Should all of the asserted claims be found invalid, this litigation would be "simplified" because it would be concluded. Alternatively, should even some of the asserted claims be found invalid, that finding would reduce the number of issues left to be litigated. *See Neste Oil OYJ v. Dynamic Fuels, LLC*, 2013 WL 3353984, at \*4 (D. Del. Jul. 2, 2013); *Gioello Enters. Ltd. v. Mattel, Inc.*, 2001 WL 125340, at \*1 (D. Del. Jan. 29, 2001). Should the claims survive the IPR process, this Court will benefit from the PTAB's expertise and review. *Canatelo LLC v. Axix Commc'ns AB*, 2014 WL 12774920, at \*2 n.3 (D. Del. May 14, 2014). Moreover, if some or all of the claims are found not invalid, litigation is likely to be simplified due to the estoppel effect on Defendants of the PTAB findings relating to certain prior art. Thus, the simplification factor favors a stay.

#### **Stage of Litigation**

In considering the stage of litigation, the court considers "whether discovery is complete and whether a trial date has been set." First Am. Title Ins. Co. v. MacLaren LLC, 2012 WL 769601, at \*4 (D. Del. Mar. 9, 2012). Staying a case in its early stages advances judicial efficiency and prevents the court and the parties from expending resources on claims that may be rendered invalid. See SenoRx, Inc. v. Hologic, Inc., 2013 WL 144255, at \*5-6 (D. Del. Jan. 11, 2013). Indeed, "stays are favored when the most burdensome stages of the case—completing discovery, preparing expert reports, filing and responding to pretrial motions, preparing for trial, going through the trial process, and engaging in post-trial motions practice—all lie in the future." Bio-Rad Laboratories, Inc. v. 10X Genomics, Inc., Civ. A. No. 18-1679, D.I. 123 at \*2 (D. Del. Jun. 2, 2020). Here, the parties are at the earliest stages of discovery. As such, this factor weighs in favor of a stay.

## **BY THE COURT:**

/s/ Nitza I. Quiñones Alejandro
NITZA I. QUIÑONES ALEJANDRO
Judge, United States District Court

In sum, this Court find that all of the relevant factors weigh in favor of a stay of this litigation. Accordingly, Defendants' motion to stay this matter is granted.